BWM-02

BWM-02 is a preclinical-stage small interfering RNA (siRNA) therapeutic candidate developed by Chengdu Xinzhenghe Pharmaceutical Technology, a subsidiary of Argo Biopharma. The drug is designed to treat rare genetic muscle diseases by utilizing the RNA interference (RNAi) pathway to specifically target and degrade messenger RNA (mRNA) transcripts associated with disease pathogenesis. By silencing the expression of a specific pathogenic gene, BWM-02 aims to inhibit the production of proteins that contribute to muscle degeneration or dysfunction. As part of Argo Biopharma's specialized pipeline for neuromuscular disorders, BWM-02 represents an application of their proprietary siRNA delivery and stabilization platform to address unmet needs in rare genetic conditions where traditional therapeutic modalities may be limited.